RemeGen Co

RemeGen Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RemeGen Co (688331.SS) as of Oct 27, 2026 is 721.43 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -1.23 B CNY — a change of -158.59% (higher).

EBITDA

721.43 MCNY

YoY

-158.59%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RemeGen Co is 2025 721.43 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RemeGen Co was 2024 -1.23 B CNY. It decreases by -158.59% higher compared to the previous year.

The RemeGen Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-243.17 M CNY
Jan 1, 2019
-421.12 M CNY
Jan 1, 2020
-707.67 M CNY
Jan 1, 2021
162.84 M CNY
Jan 1, 2022
-859.00 M CNY
Jan 1, 2023
-1.32 B CNY
Jan 1, 2024
-1.23 B CNY
Jan 1, 2025
721.43 M CNY
The RemeGen Co EBITDA history
YEAREBITDAYoY
721.43 MCNY-158.59%
-1.23 BCNY-7.05%
-1.32 BCNY+54.21%
-859.00 MCNY-627.52%
162.84 MCNY-123.01%
-707.67 MCNY+68.04%
-421.12 MCNY+73.18%
-243.17 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RemeGen Co is 721.43 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RemeGen Co changed from -1.23 B CNY to 721.43 M CNY, representing a -158.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s RemeGen Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — RemeGen Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — RemeGen Co